SEARCH

SEARCH BY CITATION

References

  • Abdool Karim SS, Churchyard GJ, Abdool Karim Q & Lawn SD (2009) HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374(9693), 921933.
  • Amor Y, Nemser B, Singh A, Sankin A & Schluger N (2008) Underreported threat of multidrug-resistant tuberculosis in Africa. Emerging Infectious Diseases 14, 13451352.
  • Balabanova Y, Ruddy M, Hubb J et al. (2005) Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. European Journal of Clinical Microbiology and Infectious Diseases 24, 136139.
  • Caminero JA (2008) Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Programme implementation. The International Journal of Tuberculosis and Lung Disease 12, 869877.
  • Centers for Disease Control and Prevention (2006) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide. Morbidity and Mortality Weekly Report 55, 301305.
  • Chan ED, Laurel V, Strand MJ et al. (2004) Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine 169, 11031109.
  • Chiang C-Y, Yu M-C, Bai K-J, Lin T-P & Lee Y-C (2001) Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. The International Journal of Tuberculosis and Lung Disease 5, 272277.
  • Chiang C-Y, Enarson DA, Yu M-C et al. (2006) Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. European Respiratory Journal 28, 980985.
  • Chiang C-Y, Caminero JA & Enarson DA (2009) Reporting on multidrug-resistant tuberculosis: a proposed definition for the treatment outcome ‘failed”. The International Journal of Tuberculosis and Lung Disease 13, 548550.
  • Chirenda J, Menzies H, Moalosi G et al. (2009) The trend of resistance to anti-tuberculosis drugs in Botswana: results from the 4th national anti-tuberculosis drug resistance survey. 40th Union World Conference on Lung Health. Int J TB Lung Dis, Cancun, Mexico.
  • Churchyard G, Kaplan G, Fallows D, Wallis RS, Onyebujoh P & Rook GA (2009) Advances in immunotherapy for Tuberculosis treatment. Clinics in Chest Medicine. Tuberculosis volume, Eds A. Zumla and S. Schaaf. 30(4), 769796.
  • Dheda K, Shean K, Zumla A et al. (2010) Early treatment outcomes of extensively drug-resistant tuberculosis in South Africa are poor regardless of HIV status. The Lancet 375, 17981807.
  • Dravniece G, Cain KP, Holtz TH, Riekstina V, Leimane V & Zaleskis R (2009) Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. European Respiratory Journal 34, 180183.
  • Dubrovina I, Miskinis K, Lyepshina S et al. (2008) Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? The International Journal of Tuberculosis and Lung Disease 12(7),756762.
  • Elliott AM, Halwiindi B, Hayes RJ et al. (1993) The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. Journal of Tropical Medicine and Hygiene 96, 111.
  • Espinal MA (2003) Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. The International Journal of Tuberculosis and Lung Disease 7, 607608.
  • Espinal MA, Kim SJ, Suarez PG et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 283, 25372545.
  • Espinal MA, Laszlo A, Simonsen L et al. (2001) Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. New England Journal of Medicine 344(17), 12941303.
  • Flament-Saillour M, Robert J, Jarlier V & Grosset J (1999) Outcome of multi-drug-resistant tuberculosis in France. A nationwide case–control study. American Journal of Respiratory and Critical Care Medicine 160, 587593.
  • Gandhi NR, Moll A, Sturm AW et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis in a rural area of South Africa. The Lancet 368, 15751580.
  • Gandhi NR, Shah NS, Andrews JR et al. (2010a) HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Tugela Ferry Care and Research (TF CARES) Collaboration. American Journal of Respiratory and Critical Care Medicine 181(1), 8086.
  • Gandhi N, Nunn P, Dheda K et al. (2010b) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet 375(9728), 18301843.
  • Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L & Horsburgh CR Jr (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. New England Journal of Medicine 328, 527532.
  • Grobusch MP (2010) Drug-resistant and extensively drug-resistant tuberculosis in southern Africa. Current Opinion in Pulmonary Medicine 16(3), 180185.
  • Habeenzu C, Mitarai S, Lubasi D et al. (2007) Tuberculosis and multidrug resistance in Zambian prisons, 2000–2001. The International Journal of Tuberculosis and Lung Disease 11, 12161220.
  • Hoek KG, Gey van Pittius NC, Moolman-Smook H et al. (2008) Fluorometric assay for testing rifampin susceptibility of Mycobacterium tuberculosis complex. Journal of Clinical Microbiology 46, 13691373.
  • Holtz TH & Cegielski JP (2007) Origin of the term XDR-TB. European Respiratory Journal 30, 396.
  • Holtz TH, Riekstina V, Zarovska E et al. (2005) XDR-TB: extreme drug-resistance and treatment outcome under DOTS-Plus, Latvia, 2000–2002. The International Journal of Tuberculosis and Lung Disease 9(Suppl. 1), S258.
  • Iseman MD, Madsen L, Goble M & Pomerantz M (1990) Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. The American Review of Respiratory Disease 141, 623625.
  • Johnson R, Streicher E, Louw GE et al. (2009) Drug resistance in Mycobacterium tuberculosis. Current Issues in Molecular Biology 8, 97112.
  • Kehinde AO, Obaseki FA, Ishola OC & Ibrahim KD (2007) Multidrug resistance to Mycobacterium tuberculosis in a tertiary hospital. Journal of the National Medical Association 99, 11851189.
  • Kim HJ, Hong YP, Kim SJ, Lew WJ & Lee EG (2001) Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. The International Journal of Tuberculosis and Lung Disease 5, 11291136.
  • Kingkaew N, Sangtong B, Amnuaiphon W et al. (2009) HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. International Journal of Infectious Diseases 13(6), 722729.
  • Korenromp EL, Scano F, Williams BG et al. (2003) Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clinical Infectious Diseases 37, 101112.
  • Kranzer K, Bekker LG, Van Schaik N et al. (2010) Community health care workers in South Africa are at increased risk for tuberculosis. South African Medical Journal 100(4), 224226. No abstract available.
  • Lalloo UG & Pillay S (2008) Managing tuberculosis and HIV in sub-Sahara Africa. Current HIV/AIDS Reports 5(3), 132139. Review.
  • Laserson KF, Thorpe LE, Leimane V et al. (2005) Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease 9, 640645.
  • Lienhardt C, Vernon A & Raviglione MC (2010) New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine 16(3), 186193.
  • Ma Z, Lienhardt C, McIlleron H, Nunn AJ & Wang X (2010) Global tuberculosis drug development pipeline: the need and the reality. The Lancet [Epub ahead of print].
  • Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC & Angeby K (2008) The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 62, 5664.
  • Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E & Raviglion M (2007) Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Review of Anti-infective Therapy 5(5), 857871.
  • Meskel DW, Abate G, Lakew M, Goshu S & Aseffa A (2008) Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital. Ethiopian Medical Journal 46, 219225.
  • Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M & Raviglione MC (2002) Frequency of recurrence among MDR-TB cases ‘successfully’ treated with standardised short-course chemotherapy. The International Journal of Tuberculosis and Lung Disease 6, 858864.
  • Migliori GB, Besozzi G, Girardi E et al. (2007a) Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal 30(4), 623626.
  • Migliori GB, Ortmann J, Girardi E et al. (2007b) Extensively drug-resistant tuberculosis, Italy and Germany. Emerging Infectious Diseases 13(5), 780782.
  • Migliori GB, Richardson MD, Sotgiu G & Lange C (2009) Multidrug-resistant and extensively drug-resistant tuberculosis in the West, Europe and United States: epidemiology, surveillance, and control. Clinics in Chest Medicine 30, 637665.
  • Migliori GB, Centis R, Lange C, Richardson MD & Sotgiu G (2010) Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Current Opinion in Pulmonary Medicine 16(3), 171179.
  • Moore DA, Evans CA, Gilman RH et al. (2006) Microscopic-observation drug-susceptibility assay for the diagnosis of TB. New England Journal of Medicine 355, 15391550.
  • Motus IY, Skorniakov SN, Sokolov VA et al. (2006) Reviving an old idea: can artificial pneumothorax play a role in the modern management of tuberculosis? The International Journal of Tuberculosis and Lung Disease 10, 571577.
  • O’Donnell MR, Padayatchi N, Master I, Osburn G & Horsburgh CR (2009) Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. The International Journal of Tuberculosis and Lung Disease 13(7), 855861.
  • Pablos-Méndez A, Raviglione MC, Laszlo A et al. (1998) Global surveillance for antituberculosis-drug resistance, 1994–1997. The New England Journal of Medicine 338(23), 16411649.
  • Pai M, Kalantri S & Dheda K (2006) New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Review of Molecular Diagnostics 6, 423432.
  • Park SK, Kim CT & Song SD (1998) Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. The International Journal of Tuberculosis and Lung Disease 2, 877884.
  • Pietzka AT, Indra A, Stoger A et al. (2009) Rapid identification of multidrug-resistant Mycobacterium tuberculosis isolates by rpoB gene scanning using high-resolution melting curve PCR analysis. Journal of Antimicrobial Chemotherapy 63, 11211127.
  • Pillay M & Sturm AW (2010) Nosocomial transmission of the F15/LAM4/KZN genotype of Mycobacterium tuberculosis in patients on tuberculosis treatment. The International Journal of Tuberculosis and Lung Disease 14(2), 223230.
  • Quy HTW, Lan NTN, Borgdorff MW et al. (2003) Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? The International Journal of Tuberculosis and Lung Disease 7, 631636.
  • Saravia JC, Appleton SC, Rich ML, Sarria M, Bayona J & Becerra MC (2005) Retreatment strategies when first-line tuberculosis therapy fails. The International Journal of Tuberculosis and Lung Disease 9, 421429.
  • Schaaf S & Dheda K (2009) Multidrug and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clinics in Chest Medicine Eds A. Zumla and S. Schaaf. Tuberculosis volume 300(4), 667683.
  • Schaaf S & Zumla A Eds (2009) Tuberculosis – A Comprehensive Clinical Reference, 107 Chapters. Publishers Elsevier Saunders, UK.
  • Shah NS, Wright A, Drobniewski F et al. (2005) Extreme drug resistance in tuberculosis (“XDR-TB”): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. The International Journal of Tuberculosis and Lung Disease 9(Suppl 1), S77.
  • Somocurcio JG, Sotomayor A, Shin S et al. (2007) Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 62, 416421.
  • Sonnenberg P, Murray J, Glynn JR et al. (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358, 16871693.
  • Sotgiu G, Ferrara G, Matteelli A et al. (2009) Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal 33(4), 871881.
  • TB Alliance (2010) Global alliance website http://www.tballinace.org/cptr/ (accessed 26 May 2010).
  • Torun T, Tahaoglu K, Ozmen I et al. (2007) The role of surgery and fluoroquinolones in the treatment of multidrug-reistant tuberculosis. The International Journal of Tuberculosis and Lung Disease 11, 979985.
  • Umubyeyi AN, Vandebriel G, Gasana M et al. (2007) Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. The International Journal of Tuberculosis and Lung Disease 11, 189194.
  • Wallis RS, Pai M, Menzies D et al. (2010) Biomarkers and diagnostics for tuberculosis: progress, current needs and translation into practice. The Lancet 375, 19201937.
  • WHO (2009) WHO Policy on TB Infection Control in Health-care Settings, Congregate Settings and Households. World Health Organization, Geneva.
  • WHO (2010) WHO Report 2010: Multidrug and Extensively Drug-resistant TB (MDR-/XDR-TB). 2010 Global Report on Surveillance and Response. WHO, Geneva. WHO/HTM/TB/2010.3.
  • WHO and IUATLD (2008) Anti-tuberculosis Drug Resistance in the World: Fourth Global Report. World Health Organization, Geneva.
  • World Health Organization (2007) The global MDR-TB & XDR-TB response plan 2007–2008. World Health Organization Document 2007;WHO/HTM/STB/2007.2007.387:1–s51.
  • Wright A, Zignol M, Van Deun A et al. ; for the Global Project on Anti-Tuberculosis Drug Resistance Surveillance (2009a) Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373(9678), 18611873.
  • Wright A, Zignol M, Van Deun A et al. (2009b) Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373, 18611873.
  • Zumla A & Schaaf S, Eds (2009) Clinics in Chest Medicine. Tuberculosis Volume, December 2009. Publishers Elsevier Saunders, Philadelphia, USA, p. 13.